275 related articles for article (PubMed ID: 10098743)
1. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.
Nehmé A; Baskaran R; Aebi S; Fink D; Nebel S; Cenni B; Wang JY; Howell SB; Christen RD
Cancer Res; 1997 Aug; 57(15):3253-7. PubMed ID: 9242457
[TBL] [Abstract][Full Text] [Related]
3. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
4. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
5. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
6. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
8. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
10. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
11. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
12. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
Fedier A; Erdmann R; Boulikas T; Fink D
Int J Oncol; 2006 Nov; 29(5):1303-10. PubMed ID: 17016665
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
[TBL] [Abstract][Full Text] [Related]
14. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
16. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
17. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
18. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells.
Helbig L; Damrot J; Hülsenbeck J; Köberle B; Brozovic A; Osmak M; Fiket Z; Kaina B; Fritz G
J Biol Chem; 2011 Apr; 286(15):12991-3001. PubMed ID: 21324906
[TBL] [Abstract][Full Text] [Related]
19. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
Potapova O; Haghighi A; Bost F; Liu C; Birrer MJ; Gjerset R; Mercola D
J Biol Chem; 1997 May; 272(22):14041-4. PubMed ID: 9162025
[TBL] [Abstract][Full Text] [Related]
20. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
